

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
藤本 穰	内科学講座 リウマチ・膠原病・ アレルギー内科分野	教授	博士(医学)	臨床免疫学	① Saito K, Fujimoto M, Funajima E, Serada S, Ohkawara T, Ishihara M, Yamada M, Suzuki H, Miya F, Kosaki K, Fujieda M, Naka T. Novel germline STAT3 gain-of-function mutation causes autoimmune diseases and severe growth failure. J Allergy Clin Immunol Glob. 2024 Jul 26;3(4):100312. ② Fujimoto M, Hosono Y, Serada S, Suzuki Y, Ohkawara T, Murata O, Quick A, Suzuki K, Kaneko Y, Takeuchi T, Naka T. Leucine-rich α 2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Mod Rheumatol. 2024 Aug 20;34(5):1072-1075. ③ Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, Naka T. Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis. Sci Rep. 2020;10(1):3384. ④ Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T. Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-beta-Smad2 signaling in naive helper T cells. Arthritis Res Ther. 2017;19(1):137. ⑤ Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2056-60.
村田 興則	内科学講座 リウマチ・膠原病・ アレルギー内科分野	講師	博士(医学)	リウマチ・ 膠原病内科学	①Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis. 2021; 38(3)e2021026 ②Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Yasuoka H, Yamaoka K, Koga K, Morita R, Yoshimura A, Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis—Clinical and immunological significance. Rheumatology (Oxford). 2021 Feb 16 ③Murata O, Sasaki N, Sasaki K, Kowada K, Ninomiya Y, Oikawa Y, Kobayashi H, Nakamura Y, Yamauchi K. Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus erythematosus. Neuroreport. 2015 Jan 7;26(1):27-32 ④Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T. Microscopic polyangiitis diagnosed by muscle specimen: a case report and literature review. Modern Rheumatology Case Reports. 2:2, 181-184 ⑤Sugai M, Murata O, Oikawa H, Katagiri H, Matsumoto A, Nagashima H, Sugai T, Maemondo M. A case of bone marrow involvement in sarcoidosis with crescentic glomerular lesions. Respir Med Case Rep. 2020 Aug 28;31:101202

鈴木 悠地	内科学講座 リウマチ・膠原病・ アレルギー内科分野	特任講師	博士(医学)	消化器病学 再生医療 腫瘍学 分子生物学	①Suzuki Y, Serada S, Yamashita M, Kawabata K, Takahashi T, Obata K, Jo A, Funajima E, Doki Y, Naka T. Assessing efficacy of anti-glypican-1 antibody-drug conjugate as potential therapeutic approach for gastric cancer. Gastric Cancer. 2025 In Press. ②Suzuki Y, Tasaki M, Kakisaka K, Nishiya M, Nomura T, Nakao M, Sugawara E, Takikawa Y, Ueda M. Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation. Amyloid. 2024;31:232-234. ③Suzuki Y, Kakisaka K, Sato T, Mikami R, Abe H, Sasaki T, Takikawa Y. Tc-99m GSA scintigraphy within the first 3 days after admission as an early predictor of outcome in severe acute liver injury. Sci Rep. 2021;11:12518. ④Suzuki Y, Kakisaka K, Suzuki A, Takahara T, Sasaki T, Sato T, Yonezawa T, Nitta H, Takikawa Y. A Lille model for predicting the response of severe alcoholic hepatitis to corticosteroid treatment in Japanese patients. Hepatol Res. 2019;49:758-764 ⑤Suzuki Y, Katagiri H, Wang T, Kakisaka K, Kume K, Nishizuka SS, Takikawa Y. Ductular reactions in the liver regeneration process with local inflammation after physical partial hepatectomy. Lab Invest. 2016;96:1211-1222.
駒ヶ嶺 正嗣	内科学講座 リウマチ・膠原病・ アレルギー内科分野	特任講師	博士(医学)	リウマチ・ 膠原病内科学	①Komagamine M, Komatsu N, Ling R, Okamoto K, Tianshu S, Matsuda K, Takeuchi T, Kaneko Y, Takayanagi H. Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss.Inflammation and Regeneration. 2023 Sep; 43(1):29. ②Huynh NC, Ling R, Komagamine M*, Shi T, Tsukasaki M, Matsuda K, Okamoto K, Asano T, Muro R, Pluemsakunthai W, et al.Oncostatin M-driven macrophage-fibroblast circuits as a drug target in autoimmune arthritis.Inflammation and Regeneration. 2024 Jul; 44(1):23.*（Komagamine M は Huynh NC, Ling R と共同筆頭著者；Equal contribution） ③Ando Y, Tsukasaki M, Huynh NC, Zang S, Yan M, Muro R, Nakamura K, Komagamine M, Komatsu N, Okamoto K, et al.The neutrophil-osteogenic cell axis promotes bone destruction in periodontitis.International Journal of Oral Science. 2024 Feb; 16(1):11. ④駒ヶ嶺 正嗣，高柳 広．関節リウマチの病態研究とその進歩（5）骨系細胞のシグナル伝達と病態．日本臨牀 2022; 80（増刊号4）：96–102. ⑤駒ヶ嶺 正嗣、田口 紗理、駒ヶ嶺 正隆、仲 哲治 関節リウマチにおけるメトジェクトの臨床効果および安全性の検討 第69回 日本リウマチ学会総会・学術集会（福岡）

大河原 知治	内科学講座 リウマチ・膠原病・ アレルギー内科分野	助教	学士（医学）	膠原病内科学	① Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich α-2 glycoprotein is a potential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun 2018 Apr 15;498(4):1045-1051. ② Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling. Gastric Cancer 2018 Nov;21(6):968-976. ③ Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T. Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances Tcell-mediated anti-tumor immunity by suppressing. Molecular Cancer Therapeutics 2018 Sep;17(9):1941-1950. ④ Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T. Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. Oncotarget 2018 Aug 31;9(68):32917-32928. ⑤大河原知治, 仲哲治 サイトカインの生理活性 免疫系 SOCSによる免疫制御 現況と展望 医学のあゆみ(0039-2359) 2004; 別冊サイトカイン-state of arts : 71-74.
舟嶋 英志	内科学講座 リウマチ・膠原病・ アレルギー内科分野	助教	修士（理工学）	分子生物学	① Funajima E, Ito G, Ishiyama E, Ishida K, Ozaki T. Mitochondrial localization of calpain-13 in mouse brain. Biochem Biophys Res Commun. 2022 Jun 18;609:149-155. ② Suzuki Y, Serada S, Yamashita M, Kawabata K, Takahashi T, Obata K, Jo A, Funajima E, Doki Y, Naka T. Assessing efficacy of anti-glypican-1 antibody-drug conjugate as potential therapeutic approach for gastric cancer. Gastric Cancer. 2025 Jul 22. Online ahead of print. ③ Uchida S, Serada S, Suzuki Y, Funajima E, Kitakami K, Dobashi K, Tamatani S, Sato Y, Beppu T, Ogasawara K, Naka T. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia. 2024 Apr;50:100982. ④ Funauchi M, Serada S, Hiramatsu K, Funajima E, Kanda M, Nagase Y, Nakagawa S, Ohkawara T, Fujimoto M, Suzuki Y, Ueda Y, Kimura T, Naka T. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. Int J Cancer. 2024 Feb 1;154(3):425-433. ⑤ 舟嶋英志, 世良田聡, 鈴木悠地, 仲哲治 第29回日本がん分子標的治療学会学術集会「Glypican-1 を標的とした抗体薬物複合体と免疫チェックポイント阻害剤の併用投与による相乗的な抗腫瘍効果の検討」